What does Vivodyne do?
Vivodyne develops lab-grown 3D human tissues that enable large-scale clinical testing and recapitulate the complexity of human disease, offering pharmaceutical companies more accurate preclinical assessments.
How much did they raise?
The company raised $40M in Series A funding, led by Khosla Ventures and joined by Lingotto Investment Management, Helena Capital, Fortius Ventures, Kairos Ventures, CS Ventures, Bison Ventures, and MBX Capital.
What are their plans for the money?
The funds will be used to scale its robotics and AI approach and ramp up R&D efforts, which may improve drug discovery processes and increase success rates in human trials.
What have they achieved so far?
Vivodyne has already demonstrated its ability to replicate the complexity of human tissues in a lab setting, attracting pharmaceutical companies looking to enhance the accuracy of their preclinical testing.
